SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF), through its subsidiary GlucaPharm Inc., is advancing GEP-44, a patented triple agonist peptide targeting GLP-1 and peptide YY receptors, as the global obesity and metabolic disease market continues to expand rapidly. The company is pursuing a differentiated approach focused on improved efficacy, tolerability and delivery flexibility in a therapeutic category that has become one of the most commercially significant in modern healthcare, with long-term market projections exceeding $200 billion.
SureNano is part of an increasingly competitive GLP-1 landscape led by major pharmaceutical companies including Eli Lilly and Company (NYSE: LLY), Novo Nordisk A/S (NYSE: NVO), Amgen Inc. (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE). Industry momentum continues accelerating as these large-cap incumbents advance next-generation obesity and diabetes therapies through new formulations, expanded indications and reduced-frequency dosing strategies aimed at improving patient access and adherence.
While large-cap incumbents dominate the current market with blockbuster GLP-1 products, SureNano is positioning itself as an emerging microcap participant focused on preclinical innovation, alternative delivery technologies and broader platform opportunities that may extend beyond metabolic disease therapeutics. The company’s initial business involves the sale and distribution of the SureNano™ surfactant, a ready-to-mix food grade compound for high performance nanoemulsions, but it is now developing into a pharmaceutical-focused company through the advancement of GEP-44.
For more details, visit the full press release here.
